Abetalipoproteinemia management market seen growing to $0.72 billion by 2030

The global abetalipoproteinemia management market is projected to grow from $0.48 billion in 2025 to $0.72 billion by 2030, driven by better genetic testing, more personalized care and wider use of vitamin-based and dietary therapies. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - The market is tied to treatment for a rare inherited disorder that can cause fat malabsorption, vitamin deficiencies, developmental delays, vision impairment and neurological complications. - Growth in diagnosis and care could expand access to specialized management for children and adults with rare genetic disease. - The report points to rising demand for molecular testing, personalized medicine and nutrition-based therapy as the main commercial drivers.

What happened: - The Business Research Company released its "Abetalipoproteinemia Management Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report estimates the market at $0.48 billion in 2025 and $0.52 billion in 2026. - The market is forecast to reach $0.72 billion by 2030. - The report covers regional dynamics across North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available. - The full market report is available online.

The details: - The report says the market grew on limited awareness of abetalipoproteinemia, dependence on traditional vitamin supplementation, restricted access to molecular diagnostics and expanded hospital-based diagnosis programs. - The forecast growth is linked to next-generation sequencing, PCR testing, gene therapy progress, higher diagnosis rates in pediatric and adult patients, research into medium-chain triglyceride therapies and dietary treatment, and more personalized treatment plans. - The report highlights broader fat-soluble vitamin supplementation, wider use of molecular genetic testing, stronger pediatric care, more MCT therapy and dietary modification, and closer integration of supportive care with emerging therapies. - Abetalipoproteinemia management includes high-dose vitamins A, D, E and K plus a low-fat diet to prevent complications from nutrient deficiencies. - The report says the rising prevalence of genetic disorders is a major growth factor, as more patients survive longer because of improved treatment. - The report cites the Cystic Fibrosis Trust, which said the number of people living with cystic fibrosis in the UK rose from 11,148 in 2022 to 11,318 in 2023. - Personalized medicine is becoming a bigger driver because genomic research enables customized nutritional therapies and treatment based on a patient's genetic profile. - The report cites the Personalized Medicine Coalition, which said the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. - Nutritional and supplement-based therapies are gaining traction as more people use vitamins and other supplements to manage deficiencies. - The report cites the Council for Responsible Nutrition, which said 74% of U.S. adults take dietary supplements, 55% use them regularly and 92% of users say supplements are essential to maintaining health.

Between the lines: - The report is signaling that a tiny rare-disease market is moving from basic vitamin replacement toward more sophisticated diagnosis and individualized treatment. - North America's lead suggests the clearest commercial advantage still sits with markets that already have stronger diagnostics and care infrastructure. - Asia-Pacific's expected growth points to a second wave of demand as healthcare access, awareness and rare-disease investment improve.

What's next: - The market's next phase will likely depend on adoption of NGS and PCR testing, plus continued progress in gene therapy and nutrition-based management. - The report expects more emphasis on pediatric care, supportive therapy and patient-specific regimens as diagnosis rates rise. - The Business Research Company says its 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables. - The company provided contact details for expert inquiries through Saumya Sahay and listed its website and social media channels.